A cohort that included neoadjuvant and adjuvant selpercatinib was opened on LIBRETTO-001 for early-stage <i>RET</i> fusion-positive NSCLC with the primary endpoint of major pathologic response. The gene discussed is RET; the disease is non-small cell lung carcinoma.